NCT01513291View on ClinicalTrials.gov

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

PHASE2CompletedINTERVENTIONAL

Enrollment

237

Participants

Timeline

Start Date

February 6, 2012

Primary Completion Date

October 3, 2012

Study Completion Date

October 3, 2012

Conditions

MigraineHeadache

Interventions

DRUG

MK-6096

MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily

DRUG

Placebo

Placebo, 2 tablets, orally, once daily

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01513291 - A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) | Biotech Hunter | Biotech Hunter